Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Spontaneous reports of adverse drug reactions related to oral anticoagulants in the Czech Republic

S. Dvorackova, K. Mala-Ladova, E. Zimcikova, E. Jirsova, S. Steurbaut, AA. Kubena, J. Kolar, J. Maly

. 2021 ; 43 (4) : 948-957. [pub] 20201127

Jazyk angličtina Země Nizozemsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22004001

Grantová podpora
SVV 260 551 Charles University

E-zdroje Online Plný text

NLK ProQuest Central od 2011-02-01 do Před 1 rokem
Medline Complete (EBSCOhost) od 2011-02-01 do Před 1 rokem
Nursing & Allied Health Database (ProQuest) od 2011-02-01 do Před 1 rokem
Health & Medicine (ProQuest) od 2011-02-01 do Před 1 rokem

Background Oral anticoagulants are established drugs of choice for the prevention and treatment of thromboembolic events. However, monitoring their safety remains warranted. Objective The aim was to analyze spontaneous reports of adverse drug reactions related to oral anticoagulants in the Czech Republic. Setting Retrospective observational pharmacovigilance study. Methods Adverse drug reaction reports were obtained from the State Institute for Drug Control between January 2005 and November 2017. Reports related to warfarin, dabigatran, apixaban, and rivaroxaban received from healthcare professionals and patients were analyzed. Main outcome measure Frequency and nature of adverse drug reactions reported to oral anticoagulants. Results In total, 297 reports containing 672 adverse drug reactions were received; 269 reports were sent by healthcare professionals (85% by physicians). In 65% of all reports, reactions were due to direct oral anticoagulants. A higher total number of adverse drug reactions was associated with direct oral anticoagulants than with warfarin [reporting odds ratio (ROR): 10.76; confidence interval (CI): 8.70-13.32; p < 0.001]. Along with the increasing utilization of direct oral anticoagulants, the reporting rate gradually declined over time, especially for rivaroxaban and apixaban. Fatal outcomes were reported in 7%, mostly for dabigatran. Hemorrhagic reactions were the most frequently reported adverse drug reactions (37% associated with dabigatran, 28% with apixaban, 24% with warfarin, and 23% with rivaroxaban), and compared to warfarin, they were significantly more often associated with direct oral anticoagulants (ROR: 14.36; CI: 9.57-21.54; p < 0.001). Conclusion The number of adverse drug reaction reports related to oral anticoagulants in the Czech Republic was relatively low, compared to other studies, but 96% of the cases were serious. Data from spontaneous adverse drug reactions reporting should be further analyzed in order to obtain additional information on the safety profile of oral anticoagulants.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22004001
003      
CZ-PrNML
005      
20220127145641.0
007      
ta
008      
220113s2021 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s11096-020-01201-2 $2 doi
035    __
$a (PubMed)33245522
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Dvorackova, Simona $u Department of Social and Clinical Pharmacy, Faculty of Pharmacy in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic
245    10
$a Spontaneous reports of adverse drug reactions related to oral anticoagulants in the Czech Republic / $c S. Dvorackova, K. Mala-Ladova, E. Zimcikova, E. Jirsova, S. Steurbaut, AA. Kubena, J. Kolar, J. Maly
520    9_
$a Background Oral anticoagulants are established drugs of choice for the prevention and treatment of thromboembolic events. However, monitoring their safety remains warranted. Objective The aim was to analyze spontaneous reports of adverse drug reactions related to oral anticoagulants in the Czech Republic. Setting Retrospective observational pharmacovigilance study. Methods Adverse drug reaction reports were obtained from the State Institute for Drug Control between January 2005 and November 2017. Reports related to warfarin, dabigatran, apixaban, and rivaroxaban received from healthcare professionals and patients were analyzed. Main outcome measure Frequency and nature of adverse drug reactions reported to oral anticoagulants. Results In total, 297 reports containing 672 adverse drug reactions were received; 269 reports were sent by healthcare professionals (85% by physicians). In 65% of all reports, reactions were due to direct oral anticoagulants. A higher total number of adverse drug reactions was associated with direct oral anticoagulants than with warfarin [reporting odds ratio (ROR): 10.76; confidence interval (CI): 8.70-13.32; p < 0.001]. Along with the increasing utilization of direct oral anticoagulants, the reporting rate gradually declined over time, especially for rivaroxaban and apixaban. Fatal outcomes were reported in 7%, mostly for dabigatran. Hemorrhagic reactions were the most frequently reported adverse drug reactions (37% associated with dabigatran, 28% with apixaban, 24% with warfarin, and 23% with rivaroxaban), and compared to warfarin, they were significantly more often associated with direct oral anticoagulants (ROR: 14.36; CI: 9.57-21.54; p < 0.001). Conclusion The number of adverse drug reaction reports related to oral anticoagulants in the Czech Republic was relatively low, compared to other studies, but 96% of the cases were serious. Data from spontaneous adverse drug reactions reporting should be further analyzed in order to obtain additional information on the safety profile of oral anticoagulants.
650    _2
$a aplikace orální $7 D000284
650    _2
$a antikoagulancia $x škodlivé účinky $7 D000925
650    12
$a fibrilace síní $x farmakoterapie $7 D001281
650    _2
$a dabigatran $x škodlivé účinky $7 D000069604
650    12
$a nežádoucí účinky léčiv $x diagnóza $x epidemiologie $7 D064420
650    _2
$a lidé $7 D006801
650    _2
$a retrospektivní studie $7 D012189
650    12
$a cévní mozková příhoda $x farmakoterapie $7 D020521
650    _2
$a warfarin $x terapeutické užití $7 D014859
651    _2
$a Česká republika $x epidemiologie $7 D018153
655    _2
$a časopisecké články $7 D016428
700    1_
$a Mala-Ladova, Katerina $u Department of Social and Clinical Pharmacy, Faculty of Pharmacy in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic
700    1_
$a Zimcikova, Eva $u Department of Social and Clinical Pharmacy, Faculty of Pharmacy in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic
700    1_
$a Jirsova, Eva $u Department of Pharmacovigilance, State Institute for Drug Control, Prague, Czech Republic
700    1_
$a Steurbaut, Stephane $u Centre for Pharmaceutical Research (CePhar), Research Group Clinical Pharmacology and Clinical Pharmacy, Vrije Universiteit Brussel, Brussels, Belgium
700    1_
$a Kubena, Ales Antonin $u Department of Social and Clinical Pharmacy, Faculty of Pharmacy in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic
700    1_
$a Kolar, Jozef $u Department of Social and Clinical Pharmacy, Faculty of Pharmacy in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic
700    1_
$a Maly, Josef $u Department of Social and Clinical Pharmacy, Faculty of Pharmacy in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic. malyj@faf.cuni.cz
773    0_
$w MED00180241 $t International journal of clinical pharmacy $x 2210-7711 $g Roč. 43, č. 4 (2021), s. 948-957
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33245522 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220113 $b ABA008
991    __
$a 20220127145638 $b ABA008
999    __
$a ok $b bmc $g 1751458 $s 1155150
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 43 $c 4 $d 948-957 $e 20201127 $i 2210-7711 $m International journal of clinical pharmacy $n Int J Clin Pharm $x MED00180241
GRA    __
$a SVV 260 551 $p Charles University
LZP    __
$a Pubmed-20220113

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...